Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Date:12/9/2008

e development of most cancers, the evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis in patients with soft-tissue sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological malignancies, as well as glioblastoma. The majority of tumors expressing high levels of pAkt were high-grade, advanced stage or had other features associated with poor prognosis. High pAkt is often seen in tumors that are resistant to conventional cancer treatments, including radiotherapy, chemotherapy, endocrine therapy, and especially therapy with some of the newer biologicals.

To date, over 1,700 patients have been treated with KRX-0401 in trials conducted both in the United States and Europe. Its safety profile is distinctly different from that of most cytotoxic agents. It does not appear to cause myelosuppression (depression of the immune system that may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of perifosine are nausea, vomiting, diarrhea and fatigue, but these are either mild or non-existent in lower doses that have induced tumor regression. Responses have been seen with both daily and weekly regimens. At the doses studied, the daily regimens were better tolerated.

In Phase 1/2 trials, KRX-0401 has induced tumor regressions and/or caused disease stabilization in a variety of tumor types. KRX-0401 has shown single agent partial responses in renal
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
6. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
9. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
10. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
11. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... -- The legalization of medical and recreational marijuana is ... new economic driver – that has taken legislators by ... response to the will of the people about a ... a National Press Club Newsmakers news conference on Thursday, ... the area of marijuana legalization will discuss its far-reaching ...
(Date:7/14/2014)... 2014 Decision Resources Group finds that ... perceptions of emerging drugs for both oncologists and ... (50 medical oncologists and 50 hematological oncologists) and ... care organizations (MCOs), reveals that despite lower familiarity ... of payers say this designation will likely influence ...
(Date:7/14/2014)... HAMILTON, N.J. , July 14, 2014 /PRNewswire/ ... Group, LLC is pleased to announce that its ... the Association for the Assessment and Accreditation of ... humane treatment of animals in science worldwide through ... highest standards for animal care and use in ...
Breaking Medicine Technology:NPC Newsmaker Program: Interpreting smoke signals from the marijuana skirmish line 2Breakthrough Therapy Designation is Likely to Sway Oncologists' Confidence in An Agent and Encourage Prescribing 2Breakthrough Therapy Designation is Likely to Sway Oncologists' Confidence in An Agent and Encourage Prescribing 3Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2
... Accuray Incorporated, (Nasdaq:  ARAY), a global leader in the ... leading academic institutions using CyberKnife radiosurgery in breast cancer ... Southwestern and Fox Chase Cancer Center, will be presented ... for Radiation Oncology (ASTRO) in San Diego from October ...
... 30 Researchers from the University of Bari, Italy, ... creates a sustained viral response (SVR) and protects them ... to determine the long-term clinical outcomes of patients posttransplant ... (HCV) infection of the liver graft. ...
Cached Medicine Technology:CyberKnife Radiosurgery for Early-Stage Breast Cancer 2CyberKnife Radiosurgery for Early-Stage Breast Cancer 3CyberKnife Radiosurgery for Early-Stage Breast Cancer 4CyberKnife Radiosurgery for Early-Stage Breast Cancer 5CyberKnife Radiosurgery for Early-Stage Breast Cancer 6Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes 2
(Date:7/14/2014)... Wisconsin (PRWEB) July 14, 2014 Secure ... software security, is partnering with the Software Assurance Marketplace ... to improve the software that drives everyday life. , ... institutions and housed in the Morgridge Institute for Research, ... S&T to advance software security practices by building a ...
(Date:7/14/2014)... 13, 2014 (HealthDay News) -- Along with improving vision, ... Alzheimer,s disease and other types of dementia, a new ... of life, the researchers said. "These preliminary results ... benefits for people with dementia and their loved ones, ... Case Western Reserve University and University Hospitals Case Medical ...
(Date:7/14/2014)... 2014 (HealthDay News) -- Being physically active in middle ... disease and other types of dementia, suggest the findings ... found that physical exercise at various levels, especially in ... from the Mayo Clinic, said in an Alzheimer,s Association ... are not yet conclusive. More research is needed to ...
(Date:7/14/2014)... By Amy Norton ... -- Older adults who enjoy mentally stimulating games may have ... research suggests. The study looked at the connection between ... mental acuity for adults in their 50s and 60s. ... every other day performed better on tests of memory and ...
(Date:7/14/2014)... KeyPoint Credit Union is teaming up ... run and one-mile family fun walk. The run begins ... and finishes inside Levi’s® Stadium. , Over the past ... the Mission City Community Fund. All proceeds benefit education, ... Seasoned athletes, part-time pavement-pounders and walkers are invited to ...
Breaking Medicine News(10 mins):Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2Health News:Staying Active May Help Prevent Dementia 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3
... for patient ... care, ... Sutter Health hospitals currently in,bargaining have voted overwhelmingly to authorize a strike ... Nurses Organizing Committee announced today. There has,been no progress in bargaining over ...
... for humans, it offered immunity for at least 6 months ... anthrax vaccine proved highly effective in tests in mice and ... , After it was placed inside the animals, noses, the ... survived after they received injections of 1,000 times the lethal ...
... AMCS ),a leader in radiology and medical image and information ... the,Thomas Weisel Partners Healthcare Conference 2007 being held in Boston. ... -- Thursday, September 6, 2007 ... a.m. (Eastern Time), ...
... Cleveland-based The ScottCare,Corporation, a leader in ... telemetry, announced today that,the company has completed ... Rozinn Electronics, Inc., a privately-held market leader ... "We are very pleased to welcome ...
... BlueShield of South,Carolina has created a new division ... Davis to vice president in charge of the ... CEO M. Edward Sellers and is,responsible for enhancing ... a corporate-wide executive development program. "We are ...
... the September issue of The American Naturalist, Juan Carranza ... Javier Prez-Barber a (Macaulay Institute, United Kingdom) offer a ... to intense competition are born with lower survival expectancies ... smaller molars relative to their body size and ...
Cached Medicine News:Health News:Nurses Send Sutter a Clear Message 2Health News:Nurses Send Sutter a Clear Message 3Health News:AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007 2Health News:The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products 2Health News:S.C. BlueCross Creates Corporate Planning Unit, Promotes Davis to Vice President 2
... InterStim Therapy for Urinary Control offers ... retention and the symptoms of overactive ... significant symptoms of urgency-frequency alone or ... failed or could not tolerate more ...
... 4 Conti is a battery operated dual-channel therapy ... conditions described below. ELPHA 4 Conti also includes ... and faecal incontinence ELPHA 4 Conti provokes a ... user can feel which muscles need exercising. In ...
... Template Set is the HDR solution which ... technique. The template set consists of a ... sutured to the patient and is placed ... Grid Face Plates. The Stepper Holder is ...
A sterile, cost-effective solution to eliminating the risk of cross-contamination....
Medicine Products: